Olink Holding Ab (Publ) Stock Price, News & Analysis

Olink and Singular Genomics Systems have partnered to integrate Olink's Explore proteomics platform with Singular's G4 Sequencing Platform, utilizing Max Read kits to enable up to 4 billion reads per run. This collaboration aims to enhance throughput and reduce costs in proteomics research. The partnership reflects Olink's commitment to provide flexible solutions for its customers and extend the application portfolio for G4 users. Both companies emphasize the benefits of this integrated solution, designed to optimize sequencing choices for proteomics customers.

Olink Holding AB (Nasdaq: OLK) has collaborated with Element Biosciences to enhance the Olink® Explore high-throughput proteomics platform with the AVITI System, a next-generation sequencing platform launched in March 2022. A proof-of-concept study indicates high compatibility between the two technologies. This partnership aims to expand Olink's product accessibility and integrate advanced applications for researchers. CEO Jon Heimer emphasized the importance of making their products widely available to enhance biological understanding.

Olink Holding AB (Nasdaq: OLK) has partnered with Pharma Foods International (PFI) to utilize Olink's technology for protein analysis services in Japan. This collaboration marks PFI as the first firm in Japan to offer services using the Olink Signature Q100 platform, which will aid in their development of pharmaceuticals and functional foods. This partnership aligns with Olink's strategy to penetrate the food supplement market, leveraging PFI's 20 years of experience in the industry to meet market demands.

Olink Holding AB (Nasdaq: OLK) will participate in the 43^rd Annual Goldman Sachs Global Healthcare Conference on June 14, 2022, at 2:00 pm PT / 5:00 pm ET. Company management will take part in a fireside chat during the event. Interested parties can access a live and archived webcast of the discussion through the Investors section of Olink's website. Founded in 2016 and headquartered in Uppsala, Sweden, Olink is focused on accelerating proteomics to enhance patient outcomes through innovative scientific solutions.

Olink Holding AB (Nasdaq: OLK) reported Q1 2022 revenue of $22.7 million, a 66% increase from Q1 2021. Key drivers included a 74% growth in analysis services revenue, totaling $16.6 million. Adjusted EBITDA was ($9.1) million with a net loss of ($12.2) million, improving from a net loss of ($14.3) million in the prior year. The company maintains its 2022 revenue guidance of $138-$145 million, signaling expected growth of 45%-53%. Olink's investment in commercial and R&D initiatives is set to support continued growth.

Olink Holding AB (Nasdaq: OLK) announced its collaboration with Oxford Genomics at the University of Oxford, marking it as the first Olink certified laboratory in the UK. This partnership aims to leverage Olink's Explore platform to enhance disease research, particularly for complex conditions like Parkinson's and Alzheimer's. The advanced Olink Explore 3072 platform enables measurement of up to 3,000 proteins per sample, employing Proximity Extension Assay technology.

CEO Jon Heimer emphasized the significance of this partnership in advancing personalized medicine and accelerating drug development.

Olink Holding AB (Nasdaq: OLK) will release its first-quarter 2022 financial results on May 12, 2022, before the market opens. A conference call will follow at 8:00 am ET, where management will discuss the results. Interested investors can participate by dialing (833) 562-0120 for domestic calls or (661) 567-1096 for international calls, using Conference ID: 5650306. A live webcast will also be available on the Olink website, with an archived replay for at least 90 days.

At the Annual General Meeting (AGM) of Olink Holding AB on April 7, 2022, several key resolutions were adopted. The AGM approved the income statement and balance sheet for 2021, with no dividends declared for that financial year. The Board of Directors' composition was confirmed, including the re-election of Jon Hindar as Chair. Additionally, the AGM approved two Long Term Incentive programs, potentially diluting shares by 0.14% and 1.63%. Authorization was granted for the Board to issue new shares, limited to a dilution of 20%. The total remuneration for the Board amounted to USD 640,000.

Olink Holding AB (Nasdaq: OLK) has made its 2021 Annual Report available on its website, showcasing its commitment to advancing proteomics. The company collaborates with biopharmaceutical firms and academic institutions to enhance understanding of human biology, aiming for impactful healthcare solutions. Established in 2016, Olink operates globally, focusing on pivotal scientific discoveries across various disease areas. The report reflects Olink's dedication to both innovation and patient outcomes.